Q2 2017 13F Holders as of 30 Jun 2017
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
90,438,636
-
Total 13F shares
-
9,694,198
-
Share change
-
+6,120
-
Total reported value
-
$155,107,419
-
Price per share
-
$16.02
-
Number of holders
-
36
-
Value change
-
-$4,334,397
-
Number of buys
-
13
-
Number of sells
-
14
Institutional Holders of CRISPR Therapeutics AG - Common Stock (CRSP) as of Q2 2017
As of 30 Jun 2017,
CRISPR Therapeutics AG - Common Stock (CRSP) was held by
36 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
9,694,198 shares.
The largest 10 holders included
NEA Management Company, LLC, Abingworth LLP, CLOUGH CAPITAL PARTNERS L P, MORGAN STANLEY, FRANKLIN RESOURCES INC, New Leaf Venture Partners, L.L.C., ORBIMED ADVISORS LLC, Novo Holdings A/S, GRANAHAN INVESTMENT MANAGEMENT INC/MA, and Vivo Capital, LLC.
This page lists
36
institutional shareholders reporting positions in this security
for the Q2 2017 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.